Sutro Biopharma

Healthcare · Biotechnology

15.10$ -1.4% vs. previous close Closing price · As of: Oct 5, 2026

Statements

Balance Sheet

Sutro Biopharma (STRO) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 194 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet STRO
Line item	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	69	–	–	–	41	45	45	145	223	202	189	172	156	154	278	307	394	359	360	371	341	304	386	401	407	358	465	432	471	403	489	452	387	321	262	210	174	242	194
Current Assets	50	48	–	–	26	22	30	127	210	177	162	136	129	127	258	292	378	266	278	251	219	229	332	347	353	304	412	381	422	355	443	406	343	287	232	182	151	221	176
Cash	12	-48	–	–	22	-22	25	41	125	27	19	12	5.0	44	65	64	206	56	56	31	30	29	79	97	47	62	235	82	69	65	91	175	190	106	64	66	58	74	54
Cash & Short-Term Investments	–	48	–	–	22	22	25	123	204	171	153	125	118	115	250	281	368	251	259	230	198	209	226	324	334	276	392	355	376	313	426	388	317	249	205	168	141	203	164
Receivables	0.6	–	–	–	1.6	3.2	3.2	2.4	2.5	3.3	6.5	7.5	6.3	9.1	5.1	7.5	5.6	7.2	9.2	12	12	12	98	11	7.1	9.9	10.0	17	36	31	7.0	6.7	8.6	14	8.0	3.9	4.0	12	5.8
Inventory	–	–	–	–	–	–	0.0	–	–	0.0	–	0.0	–	–	0.0	–	–	–	–	–	0.0	0.0	–	–	0.0	-18	–	0.0	0.0	0.0	–	–	–	–	–	–	–	–	–
Property, Plant & Equipment	19	–	–	–	14	12	12	12	11	9.9	9.3	8.5	9.6	9.5	11	12	13	15	19	53	52	23	51	24	51	24	49	–	–	–	–	–	–	–	–	–	–	–	–
Total Liabilities	58	–	–	–	150	41	177	286	92	72	69	62	59	72	71	63	62	51	52	88	89	83	177	171	190	173	310	319	321	305	337	341	343	347	294	297	306	309	298
Current Liabilities	50	–	–	–	32	19	19	37	36	31	36	36	33	32	35	30	30	23	26	35	42	39	45	58	67	59	67	74	94	80	130	131	132	133	74	72	75	71	53
Short-Term Debt	–	–	–	–	15	2.0	2.0	3.2	4.7	5.8	5.8	5.8	1.0	2.9	4.5	5.9	8.8	4.5	3.1	7.7	10	14	14	15	22	18	22	13	10	6.7	6.9	7.2	7.5	7.8	8.1	8.0	7.8	7.6	6.7
Accounts Payable	3.4	–	–	–	2.9	2.7	2.7	4.6	9.3	3.4	4.5	4.5	5.6	5.8	4.9	4.9	5.5	5.9	7.6	11	6.0	11	13	12	4.8	5.1	3.9	5.5	9.4	7.5	6.1	6.2	10	8.2	4.3	7.0	7.6	5.5	3.4
Long-Term Debt	–	–	–	–	–	13	13	12	10	8.5	7.0	5.5	8.9	24	24	24	25	25	22	19	16	13	9.8	6.8	3.8	13	–	–	–	–	–	–	–	–	–	–	–	–	–
Shareholders' Equity	12	13	–	–	-109	-4.8	-132	-141	132	131	120	110	98	82	207	244	332	307	308	284	253	220	209	230	217	185	155	112	150	98	152	111	45	-26	-32	-87	-132	-67	-103
Retained Earnings	-95	–	–	–	-115	-139	-139	-149	-150	-154	-168	-181	-196	-215	-185	-168	-228	-258	-264	-295	-333	-373	-399	-418	-453	-503	-541	-590	-559	-618	-666	-714	-787	-863	-874	-931	-978	-1,016	-1,055
Shares Outstanding	–	0.0	0.0	0.7	0.7	0.7	2.2	2.3	23	2.3	2.3	2.3	2.3	23	32	38	37	46	4.6	4.6	4.6	4.6	4.7	5.2	5.7	5.9	6.0	6.1	6.1	6.1	8.1	8.2	8.3	8.3	8.5	8.5	8.6	13	17

Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings